

New trends on obesity and NAFLD in Asia

Journal of Hepatology

67, 862-873

DOI: [10.1016/j.jhep.2017.06.003](https://doi.org/10.1016/j.jhep.2017.06.003)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Endoscopic sleeve gastropasty: Case report, technique and literature review. <i>Journal of Digestive Diseases</i> , 2017, 18, 598-603.	0.7	1
2	Endoscopic sleeve gastropasty and its application to China. <i>Journal of Digestive Diseases</i> , 2017, 18, 551-555.	0.7	9
3	The pharmacological management of NAFLD in children and adolescents. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1225-1237.	1.3	19
4	Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. <i>Current Hepatology Reports</i> , 2017, 16, 317-325.	0.4	1
5	Managing HCC in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 374-381.	0.4	1
6	miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. <i>World Journal of Gastroenterology</i> , 2017, 23, 8140-8151.	1.4	63
7	Effect of Sheng-Jiang Powder on Obesity-Induced Multiple Organ Injuries in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-8.	0.5	7
8	Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 430.	1.8	56
9	The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 491-502.	1.4	103
10	Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the <sc>GO ASIA</sc> initiative. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 816-825.	1.9	54
11	Vitamin D and Nonalcoholic Fatty Liver Disease: Bi-directional Mendelian Randomization Analysis. <i>EBioMedicine</i> , 2018, 28, 187-193.	2.7	45
12	Editorial: NAFLD in Asia—clinical associations with advanced disease become clearer. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1037-1038.	1.9	0
13	Lean NAFLD: A not so benign condition?. <i>Hepatology Communications</i> , 2018, 2, 5-8.	2.0	48
14	Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern Asian Countries (1983–2007) and Predictions to 2030. <i>Gastroenterology</i> , 2018, 154, 1719-1728.e5.	0.6	70
15	Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 16-25.	1.9	77
16	Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers. <i>Medicine (United States)</i> , 2018, 97, e12026.	0.4	20
17	Effectivity of Black Tea Polyphenol in Adipogenesis Related IGF-1 and Its Receptor Pathway Through In Silico Based Study. <i>Journal of Physics: Conference Series</i> , 2018, 1093, 012037.	0.3	5
18	Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE ^{−/−} Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	1.9	17

#	ARTICLE	IF	CITATIONS
19	Editorial: hepatitis B, fatty liver and metabolic syndrome—Interaction or coexistence? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1162-1163.	1.9	0
20	Sheng-Jiang Powder Ameliorates High Fat Diet Induced Nonalcoholic Fatty Liver Disease via Inhibiting Activation of Akt/mTOR/S6 Pathway in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-9.	0.5	5
21	Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2018, 9, 662.	1.1	16
22	Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-12.	3.2	113
23	Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 993-1002.	1.9	27
24	Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	24
25	Chronic intermittent hypoxia promotes the development of experimental non-alcoholic steatohepatitis by modulating Treg/Th17 differentiation. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 1200-1210.	0.9	17
26	Flavonones from <i>Penthorum chinense</i> Ameliorate Hepatic Steatosis by Activating the SIRT1/AMPK Pathway in HepG2 Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2555.	1.8	36
27	IRE1 α aggravates ischemia reperfusion injury of fatty liver by regulating phenotypic transformation of kupffer cells. <i>Free Radical Biology and Medicine</i> , 2018, 124, 395-407.	1.3	32
28	Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease: A Prospective Analysis. <i>American Journal of Medicine</i> , 2018, 131, 1515.e1-1515.e10.	0.6	26
29	Histone modifications in fatty acid synthase modulated by carbohydrate responsive element binding protein are associated with non-alcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , 2018, 42, 1215-1228.	1.8	12
30	Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation. <i>Journal of Physiology and Biochemistry</i> , 2018, 74, 503-510.	1.3	27
31	A juvenile case with nonalcoholic steatohepatitis and traditional Korean medicine-based treatment. <i>Integrative Medicine Research</i> , 2018, 7, 206-209.	0.7	1
32	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 1349-1356.	1.8	198
33	Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. <i>Lipids in Health and Disease</i> , 2018, 17, 196.	1.2	26
34	Health and Prevention Enhancement (H-PEACE): a retrospective, population-based cohort study conducted at the Seoul National University Hospital Gangnam Center, Korea. <i>BMJ Open</i> , 2018, 8, e019327.	0.8	40
35	Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. <i>JGH Open</i> , 2018, 2, 235-241.	0.7	47
36	Obstructive Sleep Apnea Syndrome and Metabolic Diseases. <i>Endocrinology</i> , 2018, 159, 2670-2675.	1.4	73

#	ARTICLE	IF	CITATIONS
37	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	1.4	28
38	Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation. <i>Transplantation</i> , 2019, 103, 109-112.	0.5	15
39	Reappraisal of attenuated insulin sensitivity in the evolution of non-alcoholic fatty liver disease. <i>European Journal of Clinical Nutrition</i> , 2019, 73, 770-775.	1.3	3
40	Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. <i>Chemico-Biological Interactions</i> , 2019, 311, 108794.	1.7	38
41	Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 863-872.	1.1	9
42	Independent Association of Physical Activity with Nonalcoholic Fatty Liver Disease and Alanine Aminotransferase Levels. <i>Journal of Clinical Medicine</i> , 2019, 8, 1013.	1.0	13
43	The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model. <i>Archives of Physiology and Biochemistry</i> , 2021, 127, 385-389.	1.0	11
44	Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 334-335.	1.9	1
45	Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109158.	2.5	19
46	The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 684-695.	1.9	11
47	Diet Consisting of Balanced Yogurt, Fruit, and Vegetables Modifies the Gut Microbiota and Protects Mice against Nonalcoholic Fatty Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1900249.	1.5	19
48	Pharmacological Activities of <i>Alisma orientale</i> against Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: Literature Review. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-15.	0.5	19
49	From circadian clocks to non-alcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1107-1112.	1.4	8
50	Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. <i>United European Gastroenterology Journal</i> , 2019, 7, 1124-1134.	1.6	29
51	Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5037.	1.8	98
52	Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987904.	1.4	30
53	Body Mass Index and predisposition of patients to knee osteoarthritis. <i>Obesity Medicine</i> , 2019, 16, 100143.	0.5	8
54	Protective effects of polysaccharides on hepatic injury: A review. <i>International Journal of Biological Macromolecules</i> , 2019, 141, 822-830.	3.6	37

#	ARTICLE	IF	CITATIONS
55	Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-14.	3.2	139
56	Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms. <i>Frontiers in Pharmacology</i> , 2019, 10, 1190.	1.6	10
57	Non-alcoholic fatty liver disease in lean individuals. <i>JHEP Reports</i> , 2019, 1, 329-341.	2.6	98
58	Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers. <i>Current HIV Research</i> , 2019, 17, 173-182.	0.2	6
59	Novel Ultrasonographic Fatty Liver Indicator Can Predict Hepatitis in Children With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 2018, 6, 416.	0.9	15
60	Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 45.	1.2	9
61	Prospective study of perceived dietary salt intake and the risk of non-alcoholic fatty liver disease. <i>Journal of Human Nutrition and Dietetics</i> , 2019, 32, 802-809.	1.3	33
62	TNF α -Mediated Necroptosis Aggravates Ischemia-Reperfusion Injury in the Fatty Liver by Regulating the Inflammatory Response. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	29
63	Microbial metabolites in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 2019-2028.	1.4	64
64	Antiobesity Effect of Flaxseed Polysaccharide via Inducing Satiety due to Leptin Resistance Removal and Promoting Lipid Metabolism through the AMP-Activated Protein Kinase (AMPK) Signaling Pathway. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 7040-7049.	2.4	48
65	Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 638-645.	0.7	33
66	Metabolic Characteristics of a Novel Ultrasound Quantitative Diagnostic Index for Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 7922.	1.6	6
67	Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2625.	1.8	24
68	Obesity and the Mediterranean Diet: A Review of Evidence of the Role and Sustainability of the Mediterranean Diet. <i>Nutrients</i> , 2019, 11, 1306.	1.7	133
69	Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2019, 70, 1119-1133.	3.6	355
70	Ultrasound imaging in nonalcoholic liver disease: current applications and future developments. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 546-551.	1.1	18
71	Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes. <i>Frontiers in Physiology</i> , 2019, 10, 681.	1.3	14
72	The Changing Epidemiology of Primary Liver Cancer. <i>Current Epidemiology Reports</i> , 2019, 6, 104-111.	1.1	107

#	ARTICLE	IF	CITATIONS
73	THE CORRELATION OF NECK CIRCUMFERENCE AND INSULIN RESISTANCE IN NAFLD PATIENTS. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 28-33.	0.3	8
74	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999â€“2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 389-398.	3.7	616
75	The increasing clinical burden of NAFLD in Asia. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 333-334.	3.7	5
76	Jwa Kum Whan Attenuates Nonalcoholic Fatty Liver Disease by Modulating Glucose Metabolism and the Insulin Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-10.	0.5	8
77	Plasma proteome profiling discovers novel proteins associated with nonâ€“alcoholic fatty liver disease. <i>Molecular Systems Biology</i> , 2019, 15, e8793.	3.2	176
78	Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study. <i>Advances in Therapy</i> , 2019, 36, 880-895.	1.3	7
79	TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population. <i>Lipids in Health and Disease</i> , 2019, 18, 61.	1.2	12
80	Branched chain amino acids are associated with the heterogeneity of the area of lipid droplets in hepatocytes of patients with nonâ€“alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 860-871.	1.8	15
81	From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. <i>Proceedings of the Nutrition Society</i> , 2019, 78, 290-304.	0.4	36
82	Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 181-189.	1.0	21
83	Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 491-496.	0.4	13
84	A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine. <i>International Journal of Molecular Sciences</i> , 2019, 20, 752.	1.8	10
85	<i>Beta-3-adrenergic Receptor</i> rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals. <i>Disease Markers</i> , 2019, 2019, 1-13.	0.6	6
86	Diagnostic Performance of Serum Asialo-Î±1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 74, 341.	0.2	6
87	Animal Models of Hepatocellular Carcinoma Prevention. <i>Cancers</i> , 2019, 11, 1792.	1.7	10
88	Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer. <i>Medicine (United States)</i> , 2019, 98, e17098.	0.4	10
89	Association of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease with FADS2 rs3834458 Gene Polymorphism in the Chinese Han Population. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	0.7	10
90	Tesamorelin, liver fat, and NAFLD in the setting of HIV. <i>Lancet HIV,the</i> , 2019, 6, e808-e809.	2.1	5

#	ARTICLE	IF	CITATIONS
91	Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00042.	1.3	28
92	The changing epidemiology of liver diseases in the Asia-Pacific region. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 57-73.	8.2	221
93	Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 68-75.	2.5	28
94	<scp>HOMA</scp>: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1390-1395.	1.4	67
95	Non-alcoholic fatty liver disease – A global public health perspective. <i>Journal of Hepatology</i> , 2019, 70, 531-544.	1.8	1,345
96	Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). <i>Journal of Digestive Diseases</i> , 2019, 20, 163-173.	0.7	111
97	Free triiodothyronine is associated with the occurrence and remission of nonalcoholic fatty liver disease in euthyroid women. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13070.	1.7	10
98	Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 298.	1.8	98
99	Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy. <i>Internal Medicine</i> , 2019, 58, 375-380.	0.3	6
100	Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Anatomical Record</i> , 2019, 302, 193-200.	0.8	5
101	Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2019, 54, 427-436.	2.3	30
102	Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. <i>Echocardiography</i> , 2019, 36, 249-256.	0.3	11
103	Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study. <i>Annals of Nutrition and Metabolism</i> , 2019, 74, 44-52.	1.0	29
104	Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 332-341.	1.9	41
105	Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 320-329.	0.9	34
106	The correlation between fatty liver disease and chronic kidney disease. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 42-50.	0.8	16
107	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. <i>Journal of Gastroenterology</i> , 2020, 55, 330-341.	2.3	20
108	Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 572-578.	0.7	17

#	ARTICLE	IF	CITATIONS
109	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020, 41, 66-117.	8.9	134
110	International trends in hepatocellular carcinoma incidence, 1978–2012. <i>International Journal of Cancer</i> , 2020, 147, 317-330.	2.3	303
111	Caregiver perceptions of the neighborhood food environment and their relationship with the home food environment and childhood obesity in Northeast China. <i>Appetite</i> , 2020, 144, 104447.	1.8	6
112	Impacts of exercise interventions on different diseases and organ functions in mice. <i>Journal of Sport and Health Science</i> , 2020, 9, 53-73.	3.3	79
113	Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 362-369.	1.4	21
114	The relationship between obesity and other medical comorbidities. <i>Obesity Medicine</i> , 2020, 17, 100164.	0.5	26
115	Succinate GPR111 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. <i>Liver International</i> , 2020, 40, 830-843.	1.9	34
116	Liver fat accumulation assessed by computed tomography is an independent risk factor for diabetes mellitus in a population-based study: SESSA (Shiga Epidemiological Study of Subclinical) Tj ETQq1 1 0.784314 rgBTi/Overlock 10 Tf 504		
117	Epidemiological differences of common liver conditions between Asia and the West. <i>JGH Open</i> , 2020, 4, 332-339.	0.7	18
118	Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors?. <i>Liver International</i> , 2020, 40, 496-508.	1.9	39
119	Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-16.	0.5	31
120	Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. <i>Frontline Gastroenterology</i> , 2020, 11, 478-483.	0.9	11
121	Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 3-18.	5.7	121
122	Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2020, 14, 5-7.	1.9	2
123	Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192-5p Activates Macrophages Through Rictor/Akt/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 454-469.	3.6	170
124	Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population. <i>Cytokine</i> , 2020, 126, 154927.	1.4	15
125	From NAFLD to MAFLD: a redefining moment for fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2271-2273.	0.9	79
126	Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 560905.	1.6	35

#	ARTICLE	IF	CITATIONS
127	Chemerin Is Induced in Non-Alcoholic Fatty Liver Disease and Hepatitis B-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2967.	1.7	15
128	Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. <i>Journal of Digestive Diseases</i> , 2020, 21, 604-609.	0.7	5
129	Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links. <i>Life Sciences</i> , 2020, 262, 118507.	2.0	15
130	High carbohydrate and noodle/meat-rich dietary patterns interact with the minor haplotype in the 22q13 loci to increase its association with non-alcoholic fatty liver disease risk in Koreans. <i>Nutrition Research</i> , 2020, 82, 88-98.	1.3	11
131	Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 217.	0.8	19
132	Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis. <i>Frontiers in Immunology</i> , 2020, 11, 1500.	2.2	25
133	Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non-alcoholic fatty liver disease patients. <i>JGH Open</i> , 2020, 4, 929-936.	0.7	5
134	Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. <i>Lipids in Health and Disease</i> , 2020, 19, 245.	1.2	41
135	Resistance Exercise Regulates Hepatic Lipolytic Factors as Effective as Aerobic Exercise in Obese Mice. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8307.	1.2	7
136	Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin. <i>Scientific World Journal, The</i> , 2020, 2020, 1-14.	0.8	2
137	Efficacy of vitamin D supplement in children with nonalcoholic fatty liver disease. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	0.4	1
138	Alteration of Serum Phospholipid and Polyunsaturated Fatty Acid Compositions in Nonalcoholic Fatty Liver Disease in the Japanese Population: A Cross-Sectional Study. <i>Lipids</i> , 2020, 55, 599-614.	0.7	3
139	An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	82
140	Relative contribution of fat diet and physical inactivity to the development of metabolic syndrome and non-alcoholic fat liver disease in Wistar rats. <i>Physiology and Behavior</i> , 2020, 225, 113040.	1.0	3
141	Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. <i>Nutrients</i> , 2020, 12, 2433.	1.7	9
142	Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5722.	1.8	27
143	Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF- κ B and MAPK pathways and activating the Nrf2 pathway in mice. <i>International Immunopharmacology</i> , 2020, 88, 106961.	1.7	30
144	Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study. <i>Lipids in Health and Disease</i> , 2020, 19, 229.	1.2	26

#	ARTICLE	IF	CITATIONS
145	Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108375.	1.1	5
146	Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. <i>Medicine (United States)</i> , 2020, 99, e21038.	0.4	9
147	Association between sitting time and non-alcoholic fatty liver disease in South Korean population: a cross-sectional study. <i>Lipids in Health and Disease</i> , 2020, 19, 212.	1.2	14
148	<p>The Mechanism of Traditional Chinese Medicine for the Treatment of Obesity</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 3371-3381.	1.1	14
149	Neurotrophin Inhibits Lipid Accumulation by Maintaining Mitochondrial Function in Hepatocytes via AMPK Activation. <i>Frontiers in Physiology</i> , 2020, 11, 950.	1.3	3
150	<p>FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 1333-1341.	1.3	12
151	Network pharmacology reveals the multiple mechanisms of Xiaochaihu decoction in the treatment of non-alcoholic fatty liver disease. <i>BioData Mining</i> , 2020, 13, 11.	2.2	20
152	Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5999.	1.8	13
153	Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998–2035. <i>Journal of Clinical Medicine</i> , 2020, 9, 2626.	1.0	15
154	C-Peptide: A Mediator of the Association Between Serum Uric Acid to Creatinine Ratio and Non-Alcoholic Fatty Liver Disease in a Chinese Population With Normal Serum Uric Acid Levels. <i>Frontiers in Endocrinology</i> , 2020, 11, 600472.	1.5	15
155	Modulation of the Gut Microbiota by Shen-Yan-Fang-Shuai Formula Improves Obesity Induced by High-Fat Diets. <i>Frontiers in Microbiology</i> , 2020, 11, 564376.	1.5	3
156	New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 2020, 8, 603654.	0.9	23
157	Ccr12 deficiency deteriorates obesity and insulin resistance through increasing adipose tissue macrophages infiltration. <i>Genes and Diseases</i> , 2020, 9, 429-442.	1.5	10
158	National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2020, 19, 429-436.	0.4	1
159	A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	14
160	<p>Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1171-1178.	1.1	3
161	<p>Changes in Serum Nesfatin-1 After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Nonalcoholic Fatty Liver Disease</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1459-1464.	1.1	4
162	Epidemiology of nonalcoholic fatty liver disease in non–obese populations: Meta–analytic assessment of its prevalence, genetic, metabolic, and histological profiles. <i>Journal of Digestive Diseases</i> , 2020, 21, 372-384.	0.7	34

#	ARTICLE	IF	CITATIONS
163	Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2020, 19, 118.	1.2	39
164	The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 284-290.	0.5	2
165	Regional difference in the susceptibility of non-alcoholic fatty liver disease in China. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001311.	1.2	3
166	Age-period-cohort analysis of kidney cancer deaths attributable to high body-mass index in China and U.S. adults. <i>BMC Public Health</i> , 2020, 20, 882.	1.2	6
167	Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study. <i>Lipids in Health and Disease</i> , 2020, 19, 134.	1.2	10
168	Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2020, 20, 186.	0.8	20
169	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	1.8	38
170	Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study. <i>CMAJ Open</i> , 2020, 8, E429-E436.	1.1	42
171	Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2020, 14, 808-816.	1.9	22
172	Effectiveness and safety of traditional Chinese medicines for non-alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2020, 99, e20699.	0.4	1
173	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	0.8	16
174	How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 915-916.	1.4	0
175	Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. <i>Lipids in Health and Disease</i> , 2020, 19, 145.	1.2	15
176	Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. <i>EBioMedicine</i> , 2020, 57, 102849.	2.7	33
177	Estimated Cardiorespiratory Fitness Attenuates the Impacts of Sarcopenia and Obesity on Non-Alcoholic Fatty Liver in Korean Adults. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3902.	1.2	10
178	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. <i>Diagnostics</i> , 2020, 10, 159.	1.3	31
179	Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1416-1426.	1.8	17
180	Epidemiology of non-alcoholic fatty liver disease in Asia. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 1-8.	0.7	39

#	ARTICLE	IF	CITATIONS
181	Modelling NAFLD disease burden in four Asian regionsâ€”2019â€”2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	1.9	92
182	Treatment of non-alcoholic fatty liver disease â€” Current perspectives. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 22-31.	0.7	18
183	Hepatic Function and Fibrosis Assessment Via 2D-Shear Wave Elastography and Related Biochemical Markers Pre- and Post-Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2020, 30, 2251-2258.	1.1	9
184	Increase of <i>Akkermansia muciniphila</i> by a Diet Containing Japanese Traditional Medicine Bofutsushosan in a Mouse Model of Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 839.	1.7	19
185	Oleylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR- α , UCP1, and UCP2 genes. <i>Pharmacological Research</i> , 2020, 156, 104770.	3.1	37
186	Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction. <i>Hepatology International</i> , 2020, 14, 828-841.	1.9	16
187	Interleukin 22 in Liver Injury, Inflammation and Cancer. <i>International Journal of Biological Sciences</i> , 2020, 16, 2405-2413.	2.6	41
188	Global epidemiology of lean nonâ€”alcoholic fatty liver disease: A systematic review and metaâ€”analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2041-2050.	1.4	67
189	The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study. <i>Lipids in Health and Disease</i> , 2020, 19, 148.	1.2	15
190	IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease. <i>Life Sciences</i> , 2020, 256, 117997.	2.0	19
191	Effects of Vitamin D Supplementation on General and Central Obesity: Results from 20 Randomized Controlled Trials Involving Apparently Healthy Populations. <i>Annals of Nutrition and Metabolism</i> , 2020, 76, 153-164.	1.0	36
192	Non-alcoholic fatty liver disease (NAFLD) among underweight adults. <i>Clinical Nutrition ESPEN</i> , 2020, 38, 80-85.	0.5	7
193	Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFN- α -2a in Patients with Chronic Hepatitis B and the Associated Mechanism. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-10.	0.7	3
194	Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease. <i>Lipids in Health and Disease</i> , 2020, 19, 29.	1.2	18
195	Rotating night shift work and non-alcoholic fatty liver disease among steelworkers in China: a cross-sectional survey. <i>Occupational and Environmental Medicine</i> , 2020, 77, 333-339.	1.3	31
196	Sleeping Time, BMI, and Body Fat in Chinese Freshmen and Their Interrelation. <i>Obesity Facts</i> , 2020, 13, 179-190.	1.6	17
197	Burden of Disease due to Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 1-23.	1.0	53
198	Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. <i>Liver International</i> , 2020, 40, 1052-1061.	1.9	20

#	ARTICLE	IF	CITATIONS
199	Huang-Qi San improves glucose and lipid metabolism and exerts protective effects against hepatic steatosis in high fat diet-fed rats. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 109734.	2.5	21
200	Epidemiology of non-alcoholic and alcoholic fatty liver diseases. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 16-16.	1.5	296
201	Metabolic regulation of <i>Ganoderma lucidum</i> extracts in high sugar and fat diet-induced obese mice by regulating the gut-brain axis. <i>Journal of Functional Foods</i> , 2020, 65, 103639.	1.6	14
202	Current Knowledge about the Effect of Nutritional Status, Supplemented Nutrition Diet, and Gut Microbiota on Hepatic Ischemia-Reperfusion and Regeneration in Liver Surgery. <i>Nutrients</i> , 2020, 12, 284.	1.7	30
203	Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2020, 20, 10.	0.8	93
204	Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high-fat, high-cholesterol diet. <i>Journal of Digestive Diseases</i> , 2020, 21, 179-188.	0.7	7
206	Epidemiological Features of NAFLD From 1999 to 2018 in China. <i>Hepatology</i> , 2020, 71, 1851-1864.	3.6	341
207	The prevalence of determinants of obesity, metabolic syndrome and overweight in middle-aged urban women living in a megacity. <i>Family Medicine and Primary Care Review</i> , 2020, 22, 7-12.	0.1	2
208	The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease. <i>Pediatric Obesity</i> , 2020, 15, e12653.	1.4	24
209	Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. <i>Annals of Hepatology</i> , 2020, 19, 359-366.	0.6	81
210	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , 2020, 20, 88.	0.8	25
211	Sleeve Gastropasty Combined with the NLRP3 Inflammasome Inhibitor CY-09 Reduces Body Weight, Improves Insulin Resistance and Alleviates Hepatic Steatosis in Mouse Model. <i>Obesity Surgery</i> , 2020, 30, 3435-3443.	1.1	15
212	NAFLD or comorbidities, that is the question. <i>Journal of Hepatology</i> , 2020, 73, 723.	1.8	2
213	Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 75-83.	0.7	6
214	Exposure to 2,3,3',4',4',5-hexachlorobiphenyl promotes nonalcoholic fatty liver disease development in C57BL/6 mice. <i>Environmental Pollution</i> , 2020, 263, 114563.	3.7	5
215	MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line. <i>Lipids in Health and Disease</i> , 2020, 19, 76.	1.2	25
216	The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults. <i>BMC Research Notes</i> , 2020, 13, 218.	0.6	19
217	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.2	68

#	ARTICLE	IF	CITATIONS
218	Untargeted Lipidomic Analysis of Plasma from High-fat Diet-induced Obese Rats Using UHPLC-Linear Trap Quadrupole-Orbitrap MS. <i>Analytical Sciences</i> , 2020, 36, 821-828.	0.8	25
219	Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 18-18.	1.5	2
220	High-altitude chronic hypoxia ameliorates obesity-induced non-alcoholic fatty liver disease in mice by regulating mitochondrial and AMPK signaling. <i>Life Sciences</i> , 2020, 252, 117633.	2.0	24
221	Clinical profile of non-alcoholic fatty liver disease in nonobese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 257-261.	1.4	7
222	Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 996-1008.e6.	2.4	33
223	Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 947-955.	0.9	45
224	The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population. <i>Liver International</i> , 2021, 41, 81-90.	1.9	20
225	Diabetes and cardiometabolic risk in South Asian youth: A review. <i>Pediatric Diabetes</i> , 2021, 22, 52-66.	1.2	21
226	Using an improved relative error support vector machine for body fat prediction. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 198, 105749.	2.6	24
227	A novel model for predicting fatty liver disease by means of an artificial neural network. <i>Gastroenterology Report</i> , 2021, 9, 31-37.	0.6	6
228	Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101526.	0.7	47
229	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 552-560.	1.1	7
230	Outcomes with Intra-gastric Balloon Therapy in BMI ≥ 35 Non-morbid Obesity: 10-Year Follow-Up Study of an RCT. <i>Obesity Surgery</i> , 2021, 31, 781-786.	1.1	14
231	NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 734-739.	1.0	34
232	A review of non-alcoholic fatty liver disease in non-obese and lean individuals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1497-1507.	1.4	43
233	Bariatric Surgery in Vegetarians: Asia-Pacific Metabolic and Bariatric Surgery Society (APMBSS) survey of Asian surgeon experience. <i>Asian Journal of Surgery</i> , 2021, 44, 303-306.	0.2	1
234	Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101568.	0.7	6
235	Development and validation of a noninvasive clinical scoring system to predict significant fibrosis in patients with nonalcoholic fatty liver disease. <i>Clinica Chimica Acta</i> , 2021, 514, 48-53.	0.5	2

#	ARTICLE	IF	CITATIONS
236	Validation of fatty liver disease scoring systems for ultrasound diagnosed non-alcoholic fatty liver disease in adolescents. <i>Digestive and Liver Disease</i> , 2021, 53, 746-752.	0.4	5
237	Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 83-86.	4.5	2
238	Lean NAFLD: an underrecognized and challenging disorder in medicine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 351-366.	2.6	40
239	Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database. <i>Journal of Gastroenterology</i> , 2021, 56, 274-284.	2.3	19
240	A nutritional intervention that promotes increased vegetable intake in Japanese with non-alcoholic fatty liver disease: a six-month trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2022, 70, 46-53.	0.6	2
241	Role of ALDH2 in Hepatic Disorders: Gene Polymorphism and Disease Pathogenesis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 1-9.	0.7	12
242	Clinical effectiveness of liraglutide on weight loss in South Koreans. <i>Medicine (United States)</i> , 2021, 100, e23780.	0.4	13
243	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127.	1.4	22
244	DHA-enriched phosphatidylserine ameliorates non-alcoholic fatty liver disease and intestinal dysbacteriosis in mice induced by a high-fat diet. <i>Food and Function</i> , 2021, 12, 4021-4033.	2.1	19
245	Hepatocellular Carcinoma in Pakistan: An Update. , 2021, , 387-396.		1
246	Nonalcoholic Fatty Liver Disease and Obesity. <i>Journal of Postgraduate Medicine Education and Research</i> , 2021, 55, 27-35.	0.1	1
247	Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 857-871.	2.3	36
248	Pyridoxamine and Caloric Restriction Improve Metabolic and Microcirculatory Abnormalities in Rats with Non-Alcoholic Fatty Liver Disease. <i>Journal of Vascular Research</i> , 2021, 58, 121-130.	0.6	3
249	Integrated Analysis of Key Genes and Pathways Involved in Nonalcoholic Steatohepatitis Improvement After Roux-en-Y Gastric Bypass Surgery. <i>Frontiers in Endocrinology</i> , 2020, 11, 611213.	1.5	4
251	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	1.3	9
252	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , 2021, 27, 609-623.	1.4	24
253	Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. <i>Nutrition and Metabolism</i> , 2021, 18, 21.	1.3	16
254	Food Insecurity and Lipid Profile Abnormalities Are Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease (NAFLD): A Caseâ€“Control Study. <i>Ecology of Food and Nutrition</i> , 2021, 60, 508-524.	0.8	12

#	ARTICLE	IF	CITATIONS
255	Increased Frequency of Dysfunctional Siglec-7 ⁺ CD57 ⁺ PD-1 ⁺ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021, 12, 603133.	2.2	13
256	Efficacy of Interventions That Incorporate Mobile Apps in Facilitating Weight Loss and Health Behavior Change in the Asian Population: Systematic Review and Meta-analysis. <i>Journal of Medical Internet Research</i> , 2021, 23, e28185.	2.1	24
257	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021, 11, 143.	1.1	22
258	The Threat of Multiple Liver Carcinogens in the Population of Laos: A Review. <i>Livers</i> , 2021, 1, 49-59.	0.8	1
259	GSK3 inhibitor ameliorates steatosis through the modulation of mitochondrial dysfunction in hepatocytes of obese patients. <i>IScience</i> , 2021, 24, 102149.	1.9	10
260	Recent Epidemiology of Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 206-216.	1.4	54
261	Association of LDLR rs1433099 with the Risk of NAFLD and CVD in Chinese Han Population. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	2
262	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	2.0	9
263	Association of circulating adiponin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study. <i>BMC Gastroenterology</i> , 2021, 21, 131.	0.8	6
264	Qinghua Fang inhibits high-fat diet-induced non-alcoholic fatty liver disease by modulating gut microbiota. <i>Annals of Palliative Medicine</i> , 2021, 10, 3219-3234.	0.5	4
265	NAFLD in lean individuals: not a benign disease. <i>Gut</i> , 2022, 71, 234-236.	6.1	13
266	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	1.4	5
267	The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. <i>Scientific Reports</i> , 2021, 11, 5195.	1.6	25
268	Nonalcoholic Fatty Liver Disease: A Global Perspective. <i>Clinical Therapeutics</i> , 2021, 43, 473-499.	1.1	38
269	Neck circumference as an independent predictor for NAFLD among postmenopausal women with normal body mass index. <i>Nutrition and Metabolism</i> , 2021, 18, 30.	1.3	10
270	Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. <i>BMC Gastroenterology</i> , 2021, 21, 135.	0.8	8
271	Inhaled exposure to air fresheners aggravated liver injury in a murine model of nonalcoholic fatty acid liver disease. <i>Heliyon</i> , 2021, 7, e06452.	1.4	0
272	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	1.4	26

#	ARTICLE	IF	CITATIONS
273	Secure intravariceal sclerotherapy with red dichromatic imaging decreases the recurrence rate of esophageal varices: A propensity score matching analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 431-442.	1.4	5
274	Undiagnosed liver diseases. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 28-28.	1.5	11
275	Healthy Food on the Twitter Social Network: Vegan, Homemade, and Organic Food. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3815.	1.2	24
276	Assessment of the association between body composition and risk of non-alcoholic fatty liver. <i>PLoS ONE</i> , 2021, 16, e0249223.	1.1	12
277	Relationship between dietary macronutrient composition and non-alcoholic fatty liver disease in lean and non-lean populations: a cross-sectional study. <i>Public Health Nutrition</i> , 2021, 24, 6178-6190.	1.1	9
278	Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. <i>Gene</i> , 2021, 775, 145431.	1.0	13
279	Serum Creatinine-to-Cystatin C Ratio in the Progression Monitoring of Non-alcoholic Fatty Liver Disease. <i>Frontiers in Physiology</i> , 2021, 12, 664100.	1.3	8
280	Low serum vitamin D concentrations are associated with obese but not lean NAFLD: a cross-sectional study. <i>Nutrition Journal</i> , 2021, 20, 30.	1.5	6
281	Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry. <i>Journal of Translational Medicine</i> , 2021, 19, 152.	1.8	25
282	Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e529-e534.	0.8	14
283	Tsukushi and TSKU genotype in obesity and related metabolic disorders. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2645-2654.	1.8	9
284	Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 1419-1434.	1.4	34
285	Maternal obesity accelerated non-alcoholic fatty liver disease in offspring mice by reducing autophagy. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 716.	0.8	5
286	Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status. <i>Nutrients</i> , 2021, 13, 1720.	1.7	12
287	Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients. <i>BMC Endocrine Disorders</i> , 2021, 21, 100.	0.9	5
288	Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 417-429.	1.8	7
289	The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population. <i>Lipids in Health and Disease</i> , 2021, 20, 50.	1.2	9
290	Waist-to-height ratio and non-alcoholic fatty liver disease in adults. <i>BMC Gastroenterology</i> , 2021, 21, 239.	0.8	20

#	ARTICLE	IF	CITATIONS
291	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 451-458.	1.4	37
292	Value of Visceral Fat Area and Resting Energy Expenditure in Assessment of Metabolic Characteristics in Obese and Lean Nonalcoholic Fatty Liver Disease. <i>Turkish Journal of Gastroenterology</i> , 2021, 32, 116-122.	0.4	1
293	A fuzzy-weighted Gaussian kernel-based machine learning approach for body fat prediction. <i>Applied Intelligence</i> , 2022, 52, 2359-2368.	3.3	8
294	New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3957-e3968.	1.8	10
295	Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002145.	1.2	8
296	Transition Patterns of Weight Status and Their Predictive Lipid Markers Among Chinese Adults: A Longitudinal Cohort Study Using the Multistate Markov Model. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2661-2671.	1.1	2
297	Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2909-2922.	0.8	9
298	Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study. <i>BMJ Open</i> , 2021, 11, e044237.	0.8	0
299	Alleviating effect of <i>Ficus racemosa</i> in high-fat-high-fructose diet-induced non-alcoholic fatty liver disease. <i>Indian Journal of Physiology and Pharmacology</i> , 0, 65, 12-20.	0.4	2
300	Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 200, 114058.	1.4	8
301	Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2021, 8, 691696.	1.2	43
302	Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3340-3355.	1.1	6
303	Effects of microwave technology on the subcutaneous abdominal fat and anthropometric indices of overweight adults: A clinical trial. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 1482-1488.	0.8	7
304	Kaempferol Alleviates Steatosis and Inflammation During Early Non-Alcoholic Steatohepatitis Associated With Liver X Receptor 1-lysophosphatidylcholine Acyltransferase 3 Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 690736.	1.6	23
305	Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 12097.	1.6	8
306	Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-6.	0.6	3
307	Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients. <i>Medicine (United States)</i> , 2021, 100, e26436.	0.4	7
308	Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3161-3172.	1.1	5

#	ARTICLE	IF	CITATIONS
309	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
310	Elevated liver enzymes in hospitalized patients with COVID-19 in Singapore. <i>Medicine (United States)</i> , 2021, 100, e26719.	0.4	3
311	Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 466-474.	0.4	3
312	How will NAFLD change the liver transplant landscape in the 2020s?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101759.	0.7	3
313	High frequency and long persistency of ballooning hepatocyte were associated with glucose intolerance in patients with severe obesity. <i>Scientific Reports</i> , 2021, 11, 15392.	1.6	7
314	Hydrothermal synthesis of flower-like Cr ₂ O ₃ -doped In ₂ O ₃ nanorods clusters for ultra-low isoprene detection. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2021, 620, 126606.	2.3	26
315	The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 120, 154779.	1.5	23
316	Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 7884-7897.	2.4	63
317	Crosstalk between beta-adrenergic and insulin signaling mediates mechanistic target of rapamycin hyperactivation in liver of high-fat diet-fed male mice. <i>Physiological Reports</i> , 2021, 9, e14958.	0.7	3
318	Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. <i>Frontiers in Pediatrics</i> , 2021, 9, 667247.	0.9	6
319	Current Options and Future Directions for NAFLD and NASH Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7571.	1.8	43
320	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nationwide Cohort Study. <i>Hepatology</i> , 2021, 74, 2988-2997.	3.6	10
321	Pharmacological benefits of <i>Acacia</i> against metabolic diseases: intestinal-level bioactivities and favorable modulation of gut microbiota. <i>Archives of Physiology and Biochemistry</i> , 2024, 130, 70-86.	1.0	5
322	Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population. <i>Lipids in Health and Disease</i> , 2021, 20, 92.	1.2	1
323	Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 722-723.	1.9	4
324	Application of computer tongue image analysis technology in the diagnosis of NAFLD. <i>Computers in Biology and Medicine</i> , 2021, 135, 104622.	3.9	32
325	Metabolic Changes of Hepatocytes in NAFLD. <i>Frontiers in Physiology</i> , 2021, 12, 710420.	1.3	46
326	The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 454-461.	1.8	70

#	ARTICLE	IF	CITATIONS
327	Current-Visit and Next-Visit Prediction for Fatty Liver Disease With a Large-Scale Dataset: Model Development and Performance Comparison. <i>JMIR Medical Informatics</i> , 2021, 9, e26398.	1.3	0
328	Aldehyde Dehydrogenase Mutation Exacerbated High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease with Gut Microbiota Remodeling in Male Mice. <i>Biology</i> , 2021, 10, 737.	1.3	6
329	Hepatic Lipidomics Analysis Reveals the Ameliorative Effects of Highland Barley β -Glucan on Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 9287-9298.	2.4	21
330	Inverse Association between Serum 25-hydroxyvitamin D Levels and Risk of Suspected Non-Alcoholic Fatty Liver Disease in Obese Population. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8682.	1.2	4
331	The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 680664.	1.1	7
332	Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPAR α /CD36 signaling pathway. <i>Cellular Signalling</i> , 2021, 84, 110043.	1.7	13
333	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1545-1553.	1.0	8
334	The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017. <i>Environmental Health and Preventive Medicine</i> , 2021, 26, 91.	1.4	16
335	The Prevalence, Popular Trends, and Associated and Predictive Factors of Non-Obese Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 744710.	1.5	4
336	Body fat percentage in adolescents is a better predictor of exercise effect on adiposity changes: a 4-year follow-up study. <i>Annals of Palliative Medicine</i> , 2021, 10, 9415-9426.	0.5	0
337	Changing clinical management of NAFLD in Asia. <i>Liver International</i> , 2022, 42, 1955-1968.	1.9	18
338	Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-13.	0.5	14
339	A Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non-Alcoholic Fatty Liver Disease in Non-Obese Population. <i>Cureus</i> , 2021, 13, e17869.	0.2	1
340	Nonobese mice with nonalcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways. <i>FEBS Open Bio</i> , 2021, 11, 2950-2965.	1.0	4
341	Body composition and risk of non-alcoholic fatty liver disease: A case control study. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2022, 15, 59-67.	0.2	0
342	Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2138-2147.e10.	2.4	237
343	Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. <i>Journal of Hepatology</i> , 2021, 75, 795-809.	1.8	94
344	TMBIM6 regulates redox-associated posttranslational modifications of IRE1 α and ER stress response failure in aging mice and humans. <i>Redox Biology</i> , 2021, 47, 102128.	3.9	8

#	ARTICLE	IF	CITATIONS
345	Dose-response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2021, 47, 101221.	1.4	10
346	The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 811-824.	0.7	14
347	Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol. <i>Journal of Korean Medical Science</i> , 2021, 36, e145.	1.1	8
348	Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2020, 55, 731-741.	2.3	22
350	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2022, 76, 726-734.	1.8	59
352	A Low Creatinine to Body Weight Ratio Predicts the Incident Nonalcoholic Fatty Liver Disease in Nonelderly Chinese without Obesity and Dyslipidemia: A Retrospective Study. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-9.	0.7	4
353	STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. <i>Journal of Clinical Investigation</i> , 2018, 129, 546-555.	3.9	247
354	Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH). <i>Medical Science Monitor</i> , 2018, 24, 6946-6967.	0.5	25
355	Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions. <i>World Journal of Clinical Cases</i> , 2018, 6, 922-930.	0.3	32
356	Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. <i>PLoS ONE</i> , 2020, 15, e0241770.	1.1	20
357	SARCOPENIA AND SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 357-360.	0.3	4
358	Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>Hepatoma Research</i> , 2019, 2019, 42.	0.6	31
359	Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. <i>Hepatoma Research</i> , 2020, 2020, .	0.6	11
360	Hepatitis C and liver transplantation in direct acting antiviral era. <i>AME Medical Journal</i> , 0, 3, 40-40.	0.4	2
361	Cardiovascular Effects of Flavonoids. <i>Current Medicinal Chemistry</i> , 2019, 26, 6991-7034.	1.2	41
362	Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2020, 30, 15-25.	0.2	4
363	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104.	1.1	6
364	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293.	4.5	31

#	ARTICLE	IF	CITATIONS
365	Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 367-369.	4.5	4
366	Trends in the prevalence of chronic liver disease in the Korean adult population, 1998â€“2017. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 209-215.	4.5	81
367	Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats. <i>World Journal of Gastroenterology</i> , 2019, 25, 2450-2462.	1.4	51
368	Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1792-1804.	1.4	34
369	Folic acid attenuates high-fat diet-induced steatohepatitis <i>via</i> deacetylase SIRT1-dependent restoration of PPAR α . <i>World Journal of Gastroenterology</i> , 2020, 26, 2203-2220.	1.4	25
370	Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?. <i>World Journal of Gastroenterology</i> , 2020, 26, 5812-5821.	1.4	9
371	Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. <i>Endocrinology and Metabolism</i> , 2020, 35, 165.	1.3	30
372	Standardized rice bran extract improves hepatic steatosis in HepG2 cells and ovariectomized rats. <i>Nutrition Research and Practice</i> , 2020, 14, 568.	0.7	5
373	Hepatocellular Carcinoma in Asia: A Challenging Situation. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2019, 9, 27-33.	0.1	23
374	Jicama (<i>Pachyrhizus erosus</i>) fiber prevents excessive blood glucose and body weight increase without affecting food intake in mice fed with high-sugar diet. <i>Journal of Advanced Veterinary and Animal Research</i> , 2019, 6, 222.	0.5	12
375	The Effect of Alpha-Lipoic Acid on Liver Function and Metabolic Markers in Obese Patients with Non-Alcoholic Fatty Liver Disease: A Double - Blind Randomized Controlled Trial. <i>Iranian Red Crescent Medical Journal</i> , 2018, 20, .	0.5	5
376	Effects of Alpha-Lipoic Acid Supplementation on Oxidative Stress Status in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double Blind, Placebo-Controlled Clinical Trial. <i>Iranian Red Crescent Medical Journal</i> , 2018, 20, .	0.5	7
377	Males with Obesity and Overweight. <i>Journal of Obesity and Metabolic Syndrome</i> , 2020, 29, 18-25.	1.5	36
378	Fatty liver is a risk factor for liver metastasis in Chinese patients with non-small cell lung cancer. <i>PeerJ</i> , 2019, 7, e6612.	0.9	13
379	Verapamil induces autophagy to improve liver regeneration in non-alcoholic fatty liver mice. <i>Adipocyte</i> , 2021, 10, 532-545.	1.3	6
380	Prevalence of Non-alcoholic Fatty Liver Disease among Patients with Diabetes Mellitus Attending Primary Health Care Centers in Bahrain. <i>Oman Medical Journal</i> , 2022, 37, e350.	0.3	1
381	Bile Acid Receptors and the Gutâ€“Liver Axis in Nonalcoholic Fatty Liver Disease. <i>Cells</i> , 2021, 10, 2806.	1.8	39
382	Hybrid Machine Learning Model for Body Fat Percentage Prediction Based on Support Vector Regression and Emotional Artificial Neural Networks. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9797.	1.3	11

#	ARTICLE	IF	CITATIONS
383	Association between Muscle Mass Deficits and the Non-Alcoholic Fatty Liver Disease Fibrosis Score in Adults without Central Obesity. Korean Journal of Family Practice, 2021, 11, 345-351.	0.1	1
384	<i>rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 439-448.</i>	0.7	1
385	Association of genetic variations with NAFLD in lean individuals. Liver International, 2022, 42, 149-160.	1.9	33
386	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism: Clinical and Experimental, 2022, 126, 154911.	1.5	31
387	Integrated Transcriptomic and Translatomic Inquiry of the Role of Betaine on Lipid Metabolic Dysregulation Induced by a High-Fat Diet. Frontiers in Nutrition, 2021, 8, 751436.	1.6	10
388	<i>Nigella sativa and Non-Alcoholic Fatty Liver Disease: A Review of the Current Evidence. Hepatitis Monthly, 2018, In Press, .</i>	0.1	1
389	Liver Fibrosis is Associated with NAFLD Activity Score in Chronic Hepatitis B Patients with Liver Steatosis. Hepatitis Monthly, 2018, In Press, .	0.1	2
390	Fecal Microbiota Transplantation for the Treatment of Nonalcoholic Fatty Liver Disease. Exploratory Research and Hypothesis in Medicine, 2019, 4, 12-18.	0.1	6
391	The Association Between Risk Factors And Ultrasound-Based Grades Of Non-Alcoholic Fatty Liver Disease In Type-2 Diabetes Patients. Jurnal Widya Medika, 2019, 5, 47-59.	0.0	0
392	PREVENTION EFFECTS OF METHANOLIC EXTRACT OF <i>Eurycoma longifolia</i> ROOTS ON CARBON TETRACHLORIDE-INDUCED HEPATOTOXICITY IN RATS. Jurnal Farmasi Sains Dan Komunitas, 2019, 16, 1-6.	0.2	0
395	Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. Journal of Gastroenterology, 2021, 56, 1045-1061.	2.3	18
396	Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms. Biomolecules, 2021, 11, 1582.	1.8	22
397	Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease. Cells, 2021, 10, 2978.	1.8	14
399	Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis. African Health Sciences, 2020, 20, 1800-8.	0.3	6
400	Characteristics of Non-Alcoholic Fatty Liver Disease Patients at Dr. M. Djamil General Hospital Padang. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2020, 21, 171-176.	0.0	0
401	Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia. BMJ Open Gastroenterology, 2020, 7, e000535.	1.1	14
403	Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Obese and Overweight Children in the Northwest of Iran. Hepatitis Monthly, 2019, 19, .	0.1	2
404	Endoscopic Manifestations and Pathological Features of 245 Cases of Neuroendocrine Tumors in the Digestive System. Advances in Clinical Medicine, 2020, 10, 2444-2450.	0.0	0

#	ARTICLE	IF	CITATIONS
405	Predictors of nonalcoholic fatty liver disease among middle-aged Iranians. <i>International Journal of Preventive Medicine</i> , 2020, 11, 113.	0.2	6
406	Non-alcoholic Fatty Liver Disease: A Global Public Health Issue. , 2020, , 321-333.		2
407	The effect of liver enzymes on body composition: A Mendelian randomization study. <i>PLoS ONE</i> , 2020, 15, e0228737.	1.1	2
408	Upregulation of adiponectin by Ginsenoside Rb1 contributes to amelioration of hepatic steatosis induced by high fat diet. <i>Journal of Ginseng Research</i> , 2022, 46, 561-571.	3.0	5
409	First-degree family history of diabetes is associated with nonalcoholic fatty liver disease independent of glucose metabolic status. <i>Journal of Diabetes and Its Complications</i> , 2021, , 108083.	1.2	4
410	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	0.7	3
411	Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i. <i>Hawai'i Journal of Health & Social Welfare</i> , 2020, 79, 180-186.	0.2	0
412	The value of miRNAs in the prognosis of obese patients receiving bariatric surgery. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 1905-1914.	0.0	0
413	Application Progress of Gd-EOB-DTPA-Enhanced MRI T1 Mapping in Hepatic Diffuse Diseases. <i>Current Medical Imaging</i> , 2021, 17, .	0.4	0
414	Efficacy of hepatoprotector jamu formula (combination of <i>Curcuma longa</i> , <i>Curcuma xanthorrhiza</i>), Tj ETQq1 1 0.784314 rgBT /Overlook controlled trial. <i>IOP Conference Series: Earth and Environmental Science</i> , 2021, 913, 012089.	0.2	1
415	Independent associations of thyroid-related hormones with hepatic steatosis and insulin resistance in euthyroid overweight/obese Chinese adults. <i>BMC Gastroenterology</i> , 2021, 21, 431.	0.8	7
416	Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. <i>World Journal of Hepatology</i> , 2021, 13, 1584-1610.	0.8	20
417	Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 146-161.	0.4	17
418	Effect of fermented <i>Rhus verniciflua</i> stokes extract on liver function parameters in healthy Korean adults: a double-blind randomized controlled trial. <i>Trials</i> , 2021, 22, 830.	0.7	2
419	Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 11212-11220.	1.6	13
420	MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 150-163.	4.5	53
421	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
422	Serum copper, ceruloplasmin, and their relations to metabolic factors in nonalcoholic fatty liver disease: a cross-sectional study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 443-448.	0.8	4

#	ARTICLE	IF	CITATIONS
423	Adiponectin alleviates nonalcoholic fatty liver injury via regulating oxidative stress in liver cells. <i>Minerva Medica</i> , 2020, , .	0.3	2
424	One-Hour postload plasma glucose in obese indian adults with nonalcoholic fatty liver disease: An observational study from North India. <i>Indian Journal of Endocrinology and Metabolism</i> , 2021, 25, 450.	0.2	3
425	An Observational Study to Determine Severity and Complications Associated with Non-Alcoholic Fatty Liver Disease with Special Emphasis on Riskfactors. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 5498-5502.	0.2	0
426	Hepatocyte TGF β ² Signaling Inhibiting WAT Browning to Promote NAFLD and Obesity Is Associated With Let α ^{5p} . <i>Hepatology Communications</i> , 2022, 6, 1301-1321.	2.0	20
427	Genisteinâ”Opportunities Related to an Interesting Molecule of Natural Origin. <i>Molecules</i> , 2022, 27, 815.	1.7	15
428	Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 816032.	1.6	5
429	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	2.4	9
430	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunctionâ”associated fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 795-811.	1.4	21
431	The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study. <i>Hepatology International</i> , 2022, 16, 807-816.	1.9	17
432	Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques. <i>Korean Journal of Radiology</i> , 2022, 23, 13.	1.5	18
433	The nutrition transition, food retail transformations, and policy responses to overnutrition in the East Asia region: A descriptive review. <i>Obesity Reviews</i> , 2022, 23, e13412.	3.1	13
434	A sequential approach using the ageâ”adjusted fibrosisâ”4 index and vibrationâ”controlled transient elastography to detect advanced fibrosis in Korean patients with nonâ”alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 994-1007.	1.9	2
435	Association Between Neutrophil-to-Lymphocyte Ratio with Inflammatory Activity and Fibrosis in Non-alcoholic Fatty Liver Disease. , 2022, 33, 53-61.		4
436	Integrated Liver and Plasma Proteomics in Obese Mice Reveals Complex Metabolic Regulation. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100207.	2.5	12
437	Lipid droplets associated perilipins protein insights into finding a therapeutic target approach to cure non-alcoholic fatty liver disease (NAFLD). <i>Future Journal of Pharmaceutical Sciences</i> , 2022, 8, .	1.1	11
438	Sex-specific Cutoff Values of Visceral Fat Area for Lean vs. Overweight/Obese Nonalcoholic Fatty Liver Disease in Asians. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
439	Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. <i>Current Oncology Reports</i> , 2022, 24, 187-193.	1.8	10
440	Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 154-161.	0.6	24

#	ARTICLE	IF	CITATIONS
441	Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 960-969.e1.	2.4	12
442	Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	0
443	Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis. <i>Pharmaceutical Biology</i> , 2022, 60, 274-281.	1.3	13
444	Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 518-525.	1.8	94
446	Hepatoprotective mechanism of <i>Silybum marianum</i> on nonalcoholic fatty liver disease based on network pharmacology and experimental verification. <i>Bioengineered</i> , 2022, 13, 5216-5235.	1.4	24
447	Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriages—a prospective study in Rajarata Pregnancy Cohort (RaPCo). <i>BMJ Open Gastroenterology</i> , 2022, 9, e000831.	1.1	7
448	Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1180-1190.	2.8	22
449	Therapeutic developments in metabolic dysfunction-associated fatty liver disease. <i>Chinese Medical Journal</i> , 2022, Publish Ahead of Print, .	0.9	2
450	Prevalence and risk factors of metabolic-associated fatty liver disease during 2014–2018 from three cities of Liaoning Province: an epidemiological survey. <i>BMJ Open</i> , 2022, 12, e047588.	0.8	4
451	Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. <i>Scientific Reports</i> , 2022, 12, 2538.	1.6	3
452	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	1.4	14
453	Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density. <i>Frontiers in Endocrinology</i> , 2022, 13, 857110.	1.5	33
454	Adipose tissue macrophage-derived exosomes induce ferroptosis via glutathione synthesis inhibition by targeting SLC7A11 in obesity-induced cardiac injury. <i>Free Radical Biology and Medicine</i> , 2022, 182, 232-245.	1.3	35
455	Non-Alcoholic Fatty Liver Disease and Its Potential Therapeutic Strategies. , 0, , .		0
456	The association between Dietary Diversity Score and odds of nonalcoholic fatty liver disease: a case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 678-685.	0.8	9
457	Association between non-alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study. <i>Liver International</i> , 2022, 42, 1027-1036.	1.9	23
458	Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 887-896.	1.1	1
459	Visceral Fat Area Is an Independent Risk Factor for Overweight or Obese Nonalcoholic Fatty Liver Disease in Potential Living Liver Donors. <i>Transplantation Proceedings</i> , 2022, 54, 702-705.	0.3	3

#	ARTICLE	IF	CITATIONS
460	Detection and isolation of typical gut indigenous bacteria in mice fed corn starch, bread flour or whole wheat flour. , 2022, 1, 91-100.		2
461	Editorial: opposite effects of genetic polymorphisms known to induce <sc>NAFLD</sc> on hepatic and cardiovascular outcomes in Chinese population authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 878-879.	1.9	0
462	Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study. Diagnostics, 2022, 12, 663.	1.3	7
463	Empirically derived dietary pattern and odds of non-alcoholic fatty liver diseases in overweight and obese adults: a case-control study. BMC Gastroenterology, 2022, 22, 158.	0.8	6
464	Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity. Frontiers in Nutrition, 2022, 9, 808497.	1.6	4
465	Macrophage SCAP Contributes to Metaflammation and Lean NAFLD by Activating STING-NF- κ B Signaling Pathway. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 1-26.	2.3	16
466	Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model. Biomedicines, 2022, 10, 5.	1.4	7
467	Multi-echo Dixon and breath-hold T2-corrected multi-echo single-voxel MRS for quantifying hepatic iron overload in rabbits. Acta Radiologica, 2023, 64, 13-19.	0.5	3
468	Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Frontiers in Pharmacology, 2021, 12, 788558.	1.6	34
469	Immature sword bean pods (<i>Canavalia gladiata</i>) inhibit adipogenesis in C3H10T1/2 cells and mice with high-fat diet-induced obesity. Journal of the Chinese Medical Association, 2022, 85, 67-76.	0.6	10
470	Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. Diabetes, Obesity and Metabolism, 2022, 24, 752-756.	2.2	5
471	Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Bioscience Reports, 2021, 41, .	1.1	3
472	Analyzing TCGA Data to Identify Gene Mutations Linked to Hepatocellular Carcinoma in Asians. Gastrointestinal Tumors, 2022, 9, 43-58.	0.3	1
473	Protective Effect and Mechanism of Plant-Based Monoterpenoids in Non-alcoholic Fatty Liver Diseases. Journal of Agricultural and Food Chemistry, 2022, 70, 4839-4859.	2.4	10
474	Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. Frontiers in Nutrition, 2022, 9, 844374.	1.6	5
475	Rutin-activated adipose tissue thermogenesis is correlated with increased intestinal short-chain fatty acid levels. Phytotherapy Research, 2022, 36, 2495-2510.	2.8	12
476	Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse. Biomedicine and Pharmacotherapy, 2022, 150, 112984.	2.5	2
483	Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune-tolerant phase authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1094-1095.	1.9	0

#	ARTICLE	IF	CITATIONS
484	Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B. <i>World Journal of Hepatology</i> , 2022, 14, 791-801.	0.8	1
485	Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD. <i>Hepatology Communications</i> , 2022, 6, 1527-1536.	2.0	3
486	The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
487	Obeticholic Acid Induces Hepatotoxicity Via FXR in the NAFLD Mice. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
488	NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population. <i>Hepatology Communications</i> , 2022, 6, 2310-2321.	2.0	11
489	Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease. <i>Healthcare (Switzerland)</i> , 2022, 10, 850.	1.0	1
490	Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases. <i>Genes and Diseases</i> , 2023, 10, 2351-2365.	1.5	2
491	Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease. <i>World Journal of Clinical Cases</i> , 2022, 10, 4097-4109.	0.3	0
492	An examination of eating behavior in patients with non-alcoholic fatty liver disease: A cross-sectional study in a Japanese population. <i>Human Nutrition and Metabolism</i> , 2022, 28, 200150.	0.8	1
493	<i>Polygonatum sibiricum</i> polysaccharides protect against obesity and non-alcoholic fatty liver disease in rats fed a high-fat diet. <i>Food Science and Human Wellness</i> , 2022, 11, 1045-1052.	2.2	18
494	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 1082-1087.	0.7	5
495	White tea alleviates non-alcoholic fatty liver disease by regulating energy expenditure and lipid metabolism. <i>Gene</i> , 2022, 833, 146553.	1.0	5
496	Association between bilirubin and nonalcoholic fatty liver disease in the non-obese Chinese population: a cross-sectional study. <i>Annals of Translational Medicine</i> , 2022, 10, 522-522.	0.7	2
497	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4919-4928.	1.1	26
498	The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis.. <i>Croatian Medical Journal</i> , 2022, 63, 176-186.	0.2	0
499	The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis. <i>Croatian Medical Journal</i> , 2022, 63, 176-185.	0.2	3
500	The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00504.	1.3	6
502	Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic <i>de novo</i> lipogenesis. <i>Gut Microbes</i> , 2022, 14, .	4.3	18

#	ARTICLE	IF	CITATIONS
503	Modeling the Trend Changes of Liver Cancer Mortality in the 6 WHO Regions. , 0, , .		1
504	Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 559-568.	0.6	13
505	Osteopontin Promotes Macrophage M1 Polarization by Activation of the JAK1/STAT1/HMGB1 Signaling Pathway in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
506	Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	27
507	Association between the LRP5 rs556442 gene polymorphism and the risks of NAFLD and CHD in a Chinese Han population. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	2
508	Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. <i>Nutrients</i> , 2022, 14, 2361.	1.7	7
509	Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants. <i>PLoS ONE</i> , 2022, 17, e0269641.	1.1	5
510	Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity. <i>Hepatology International</i> , 2022, 16, 824-834.	1.9	6
511	Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection. <i>Arab Journal of Gastroenterology</i> , 2023, 24, 11-15.	0.4	2
512	Exploring and Verifying the Mechanism and Targets of Shenqi Pill in the Treatment of Nonalcoholic Steatohepatitis via Network Pharmacology and Experiments. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	1
513	A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4113-4123.	1.6	12
514	Evaluated Glomerular Filtration Rate Is Associated With Non-alcoholic Fatty Liver Disease: A 5-Year Longitudinal Cohort Study in Chinese Non-obese People. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	5
515	Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 396-406.	1.9	28
516	Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. <i>BMJ Open</i> , 2022, 12, e054891.	0.8	6
517	Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 573-584.	3.6	18
518	Emerging Trends and Hot Spots in Hepatic Glycolipid Metabolism Research From 2002 to 2021: A Bibliometric Analysis. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	7
519	Cutoff Points of Waist Circumference for Predicting Incident Non-Alcoholic Fatty Liver Disease in Middle-Aged and Older Korean Adults. <i>Nutrients</i> , 2022, 14, 2994.	1.7	8
520	Epidemiological trends and clinical characteristic of <sc>NAFLD</sc>/<sc>MAFLD</sc> in Asia. <i>Journal of Digestive Diseases</i> , 2022, 23, 354-357.	0.7	5

#	ARTICLE	IF	CITATIONS
521	Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
522	A Meta-Analysis of Sleep Disorders and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Nursing</i> , 2022, 45, 354-363.	0.2	0
523	Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease. <i>JGH Open</i> , 2022, 6, 696-703.	0.7	2
524	Distinct impacts of fat and fructose on the liver, muscle, and adipose tissue metabolome: An integrated view. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
525	Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPAR α /FGF21 Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 1003-1023.	2.3	8
526	GPM6A expression is suppressed in hepatocellular carcinoma through miRNA-96 production. <i>Laboratory Investigation</i> , 0, , .	1.7	1
527	Association between metabolically healthy obesity and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2022, 16, 1412-1423.	1.9	10
528	Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
529	Risk factors and prediction model for nonalcoholic fatty liver disease in northwest China. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
530	Risk Factors and Prediction Models for Nonalcoholic Fatty Liver Disease Based on Random Forest. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	0.7	2
531	Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
532	Serum Fibrinogen-Like Protein 1 Levels in Obese Patients Before and After Laparoscopic Sleeve Gastrectomy: A Six-Month Longitudinal Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 2511-2520.	1.1	2
533	MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH. <i>Journal of Molecular Endocrinology</i> , 2022, 69, 415-430.	1.1	3
534	Profile analysis and functional modeling identify circular RNAs in nonalcoholic fatty liver disease as regulators of hepatic lipid metabolism. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
535	Early life dietary emulsifier exposure predisposes the offspring to obesity through gut microbiota-FXR axis. <i>Food Research International</i> , 2022, 162, 111921.	2.9	4
536	Serum 25-hydroxyvitamin D levels and the risk of non-alcoholic fatty liver: A two-sample Mendelian randomization study. <i>Saudi Journal of Gastroenterology</i> , 2023, 29, 39.	0.5	1
537	Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study. <i>Internal Medicine</i> , 2023, 62, 1415-1423.	0.3	1
538	Unmixing multi-spectral electrical impedance tomography (EIT) predicts clinical-standard controlled attenuation parameter (CAP) for nonalcoholic fatty liver disease classification: a feasibility study. , 2022, , .		2

#	ARTICLE	IF	CITATIONS
539	Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis. <i>Chinese Medical Journal</i> , 2022, 135, 1682-1691.	0.9	16
540	Phytic Acid Improves Hepatic Steatosis, Inflammation, and Oxidative Stress in High-Fat Diet (HFD)-Fed Mice by Modulating the Gut-Liver Axis. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 11401-11411.	2.4	12
542	Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990-2019: A joinpoint and age-period-cohort analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
543	Editorial: Nonalcoholic fatty liver disease therapy: Exploring molecular mechanisms of well-defined composition from natural plants. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
544	Geographical similarity and differences in the burden and genetic predisposition of NAFLD. <i>Hepatology</i> , 2023, 77, 1404-1427.	3.6	43
546	The association between elevated body mass index and wide blood chemistry panel results in apparently healthy individuals. <i>American Journal of the Medical Sciences</i> , 2023, 365, 152-161.	0.4	1
547	Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
548	Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. <i>Cancers</i> , 2022, 14, 4473.	1.7	20
549	Association between serum uric acid-to-creatinine ratio and non-alcoholic fatty liver disease: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	5
550	Racial/ethnic differences in fibrosis prevalence and progression in biopsy-proven steatosis: A focus on the Asian American population. <i>Hepatology Communications</i> , 2022, 6, 3024-3035.	2.0	1
551	The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	0
552	Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
553	Comparison of time trends in the incidence of primary liver cancer between China and the United States: an age-period-cohort analysis of the Global Burden of Disease 2019. <i>Chinese Medical Journal</i> , 2022, 135, 2035-2042.	0.9	1
554	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. <i>Journal of Clinical Hypertension</i> , 2022, 24, 1218-1225.	1.0	1
555	A high-fat, high-fructose diet induced hepatic steatosis, renal lesions, dyslipidemia, and hyperuricemia in non-obese rats. <i>Heliyon</i> , 2022, 8, e10896.	1.4	6
556	The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e34809.	1.2	12
557	Association between physical activity and serum liver aminotransferases in Southwestern Iran: A Cross-sectional study. <i>Journal of Research in Medical Sciences</i> , 2022, 27, 79.	0.4	1
558	Fasting glucose mediates the influence of genetic variants of SOD2 gene on lean non-alcoholic fatty liver disease. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1

#	ARTICLE	IF	CITATIONS
559	Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	5
560	New insights into the characteristics of DRAK2 and its role in apoptosis: From molecular mechanisms to clinically applied potential. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
561	Hepatic Lipid Homeostasis in NAFLD. , 0, , .		0
562	Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
563	Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents. <i>Medicine (United States)</i> , 2022, 101, e31164.	0.4	16
564	Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	0
565	Triglyceride: A mediator of the association between waist-to-height ratio and non-alcoholic fatty liver disease: A second analysis of a population-based study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
566	Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12464.	1.8	2
567	Sodium Alginate Prevents Non-Alcoholic Fatty Liver Disease by Modulating the Gutâ€œLiver Axis in High-Fat Diet-Fed Rats. <i>Nutrients</i> , 2022, 14, 4846.	1.7	14
568	Association of Triglyceride-Glucose Index and Liver Function Parameters Among Healthy Obese Civil Servants: A Center-Based Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 3519-3531.	1.1	3
569	Assessing causal relationships between sarcopenia and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	6
570	Butyrate Attenuates Hepatic Steatosis Induced by a Highâ€œFat and Fiberâ€œDeficient Diet via the Hepatic GPR41/43â€œCaMKII/HDAC1â€œCREB Pathway. <i>Molecular Nutrition and Food Research</i> , 2023, 67, .	1.5	6
571	Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio has a non-linear association with non-alcoholic fatty liver disease: A secondary prospective cohort study in non-obese Chinese adults. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
572	The Association of Sarcopenia and Visceral Obesity with Lean Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-8.	1.0	6
574	Progress of Non-Drug Intervention and Traditional Chinese Medicine Treatment of Metabolic-Associated with Fatty Liver Disease. <i>Advances in Clinical Medicine</i> , 2022, 12, 10927-10932.	0.0	0
575	Residential greenness associated with decreased risk of metabolic- dysfunction-associated fatty liver disease: Evidence from a large population-based epidemiological study. <i>Ecotoxicology and Environmental Safety</i> , 2023, 249, 114338.	2.9	2
576	Association Between Liver Steatosis and Single Nucleotide Polymorphisms in the <i>PNPLA3</i> Gene in the Northern Part of Okinawa, Japan. <i>Journal of the Japanese Association of Rural Medicine</i> , 2022, 71, 309-320.	0.0	0
577	Parentsâ€™ Knowledge, Attitudes, and Practices of Childhood Obesity in Singapore. <i>SAGE Open</i> , 2022, 12, 215824402211444.	0.8	4

#	ARTICLE	IF	CITATIONS
578	Non-alcoholic fatty liver disease and liver secretome. Archives of Pharmacal Research, 2022, 45, 938-963.	2.7	4
579	The "obesity paradox" in patients with atrial fibrillation: Insights from the Gulf SAFE registry. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
580	The Effect of Walking Combined with Neuromuscular Electrical Stimulation on Liver Stiffness and Insulin Resistance in Patients with Non-alcoholic Fatty Liver Disease: An Exploratory Randomized Controlled Trial. Kurume Medical Journal, 2022, , .	0.0	0
581	Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. International Journal of Molecular Sciences, 2022, 23, 14762.	1.8	5
582	Current status of disparity in liver disease. World Journal of Hepatology, 0, 14, 1940-1952.	0.8	2
583	Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease. BMC Gastroenterology, 2022, 22, .	0.8	4
584	Characterization of signature trends across the spectrum of non-alcoholic fatty liver disease using deep learning method. Life Sciences, 2023, 314, 121195.	2.0	7
585	Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. International Journal of Molecular Sciences, 2022, 23, 15489.	1.8	43
586	Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	3
587	Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling. JCI Insight, 2022, 7, .	2.3	8
588	Strategies used by the soft drink industry to grow and sustain sales: a case-study of The Coca-Cola Company in East Asia. BMJ Global Health, 2022, 7, e010386.	2.0	5
589	Obesity in South and Southeast Asia" A new consensus on care and management. Obesity Reviews, 2023, 24, .	3.1	22
590	Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2023, 21, 2298-2307.e18.	2.4	8
591	Lower serum PRL is associated with the development of non-alcoholic fatty liver disease: a retrospective cohort study. BMC Gastroenterology, 2022, 22, .	0.8	4
592	Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. Frontiers in Physiology, 0, 13, .	1.3	5
593	Global incidence and prevalence of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2023, 29, S32-S42.	4.5	67
594	Assessing the longitudinal association between the GGT/HDL-C ratio and NAFLD: a cohort study in a non-obese Chinese population. BMC Gastroenterology, 2022, 22, .	0.8	7
595	Risk Factors for Nonalcoholic Fatty Liver Disease with Different Insulin Resistance in a Nonobese Chinese Population. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	2

#	ARTICLE	IF	CITATIONS
596	The surveillance of progression and assessment of treatment endpoint for nonalcoholic steatohepatitis. <i>Clinical and Molecular Hepatology</i> , 0, , .	4.5	0
597	Down-regulation of hepatic CLOCK by PPAR α is involved in inhibition of NAFLD. <i>Journal of Molecular Medicine</i> , 2023, 101, 139-149.	1.7	2
598	Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis. <i>Surgery for Obesity and Related Diseases</i> , 2023, 19, 717-726.	1.0	4
599	Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	12
600	Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease. <i>Annals of Hepatology</i> , 2023, 28, 100892.	0.6	2
601	Fu brick tea alleviates high fat induced non-alcoholic fatty liver disease by remodeling the gut microbiota and liver metabolism. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2
602	RANKL Is Independently Associated with Increased Risks of Non-Alcoholic Fatty Liver Disease in Chinese Women with PCOS: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 451.	1.0	4
603	Dietary patterns and risk of non-alcoholic fatty liver disease in Korean adults: a prospective cohort study. <i>BMJ Open</i> , 2023, 13, e065198.	0.8	6
604	Lipid metabolism in non-alcoholic fatty liver disease in patients with different body weights in mid-mountain conditions. <i>Terapevticheski Arkhiv</i> , 2023, 94, 1361-1366.	0.2	0
606	β -NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression. <i>BMC Endocrine Disorders</i> , 2023, 23, .	0.9	1
607	Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 667.	1.2	0
608	Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a. <i>Nutrients</i> , 2023, 15, 121.	1.7	0
609	Non-alcoholic fatty liver disease: Definition and subtypes. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S5-S16.	4.5	21
610	The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A doseâ€“response meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	8
611	Prevalence, Metabolic Profile, and Associated Risk Factors of Non-alcoholic Fatty Liver Disease in an Adult Population of India. <i>Cureus</i> , 2023, , .	0.2	0
612	Genetic variation in TBC1 domain family member 1 gene associates with the risk of lean NAFLD via high-density lipoprotein. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
613	Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis. <i>Heliyon</i> , 2023, 9, e131113.	1.4	1
614	Association of Healthy Lifestyles with Non-Alcoholic Fatty Liver Disease: A Prospective Cohort Study in Chinese Government Employees. <i>Nutrients</i> , 2023, 15, 604.	1.7	1

#	ARTICLE	IF	CITATIONS
615	Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2844.	1.8	20
616	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	3.6	358
617	Metabolic-associated fatty liver disease: pharmacological management. , 2023, , 319-341.		0
618	Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXR±/FASN Signaling. <i>Nutrients</i> , 2023, 15, 1255.	1.7	2
619	Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2023, 27, 211-223.	1.0	6
620	Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114445.	2.5	3
621	Association of PNPLA3 (rs738409) & TM6SF2 (rs58542926) and ATG16L1 (rs2241880) genetic variants with susceptibility to hepatocellular carcinoma in a group of Egyptian patients with HCV-induced liver cirrhosis. <i>Tumour Virus Research</i> , 2023, 15, 200256.	1.5	0
622	Research progress regarding the effect and mechanism of dietary phenolic acids for improving nonalcoholic fatty liver disease via gut microbiota. <i>Comprehensive Reviews in Food Science and Food Safety</i> , 2023, 22, 1128-1147.	5.9	2
623	Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 1565-1572.	1.8	3
624	Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 345-363.	1.1	3
625	Metabolic status indicators and influencing factors in non-obese, non-centrally obese nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2023, 102, e32922.	0.4	0
626	Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 13-26.	2.2	8
627	<sc>TUBB4B</sc> is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma. <i>Journal of Pathology</i> , 2023, 260, 71-83.	2.1	4
628	Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3900.	1.8	22
629	Association of Chinese Visceral Adiposity Index and Carotid Atherosclerosis in Steelworkers: A Cross-Sectional Study. <i>Nutrients</i> , 2023, 15, 1023.	1.7	3
630	Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1103-1116.	1.9	3
631	Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 0, 15, 237-254.	0.8	1
632	Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection. , 2023, , 581-599.		0

#	ARTICLE	IF	CITATIONS
633	Long-Term Resistance to Endurance Combined Training Reduces Pro-Inflammatory Cytokines in Young Adult Females with Obesity. <i>Sports</i> , 2023, 11, 54.	0.7	10
634	Swietenine Alleviates Nonalcoholic Fatty Liver Disease in Diabetic Mice via Lipogenesis Inhibition and Antioxidant Mechanisms. <i>Antioxidants</i> , 2023, 12, 595.	2.2	2
635	A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in men with obesity. <i>Endocrine</i> , 2023, 80, 54-63.	1.1	1
636	Understanding the corporate political activity of the ultra-processed food industry in East Asia: a Philippines case study. <i>Globalization and Health</i> , 2023, 19, .	2.4	6
637	Celastrol confers ferroptosis resistance via AKT/GSK3 β signaling in high-fat diet-induced cardiac injury. <i>Free Radical Biology and Medicine</i> , 2023, 200, 36-46.	1.3	4
638	Nobiletin Intake Attenuates Hepatic Lipid Profiling and Oxidative Stress in HFD-Induced Nonalcoholic-Fatty-Liver-Disease Mice. <i>Molecules</i> , 2023, 28, 2570.	1.7	5
639	Liver Lipidomics Analysis Revealed the Novel Ameliorative Mechanisms of L-Carnitine on High-Fat Diet-Induced NAFLD Mice. <i>Nutrients</i> , 2023, 15, 1359.	1.7	1
641	The triglyceride glucose index and CDKAL1 gene rs10946398 SNP are associated with NAFLD in Chinese adults. <i>Minerva Endocrinology</i> , 2023, 48, .	0.6	2
642	Possible Sources of Trace Metals in Obese Females Living in Informal Settlements near Industrial Sites around Gauteng, South Africa. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5133.	1.2	0
643	Autoantibody Positivity Has No Impact on Histological Parameters in Nonalcoholic Fatty Liver Diseases. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 730-735.	0.4	1
644	Multiple time-dependent pathophysiological changes in a rabbit model of high-fat diet-induced hyperlipidemia. <i>FEBS Open Bio</i> , 2023, 13, 1027-1040.	1.0	0
645	History of Gestational Diabetes and Incident Nonalcoholic Fatty Liver Disease: The Kangbuk Samsung Health Study. <i>American Journal of Gastroenterology</i> , 2023, 118, 1980-1988.	0.2	2
646	Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	2
647	Global epidemiology of cirrhosis – aetiology, trends and predictions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 388-398.	8.2	82
648	Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 347-355.	1.8	9
649	Evaluation of the intracellular lipid-lowering effect of polyphenols extract from highland barley in HepG2 cells. , 2024, 13, 454-461.		1
650	Higher intakes of lysine, threonine and valine are inversely associated with non-alcoholic fatty liver disease risk: a community-based case-control study in the Chinese elderly. , 2024, 13, 191-197.		3
651	Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2

#	ARTICLE	IF	CITATIONS
652	Waist circumference mediates the association between rs1260326 in GCKR gene and the odds of lean NAFLD. Scientific Reports, 2023, 13, .	1.6	2
653	Association of Non-alcoholic Fatty Liver Disease With Salt Intake and Dietary Diversity in Chinese Medical Examination Adults Aged 18â€“59 Years: A Cross-Sectional Study. Frontiers in Nutrition, 0, 9, .	1.6	6
703	Extracellular Vesicles and Fatty Liver. Advances in Experimental Medicine and Biology, 2023, , 129-141.	0.8	1
706	Effect of curcumin and zingiberone on non alcoholic fatty liver disease (NAFLD). AIP Conference Proceedings, 2023, , .	0.3	0
713	Non-alcoholic Fatty Liver Disease. , 2023, , 1-17.		0
741	Non-alcoholic Fatty Liver Disease. , 2023, , 567-583.		0